Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

ALT

Altimmune, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1326190Held by 3 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$0.0M
Net Income FY2025
$(88.0M)
EPS (Basic, as reported)
$-1.00
Net Margin FY2025
-214861.0%
ROE FY2025
-39.2%
Total Equity
$225.0M
Shares Out
195M
Business description

Altimmune, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2010–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 3 → 0
Fiscal yearFY2016FY2017FY2018FY2019⚑FY2020⚑FY2021FY2022FY2023FY2024FY2025
Revenue311106840000
Research & development(5)(18)(18)(18)(50)(75)(71)(66)(82)(66)
General & administrative(12)(8)(10)(9)(13)(15)(17)(18)(21)(28)
Total operating expenses(16)(63)(53)(27)(63)(101)(88)(96)(103)(95)
Operating income(11)(52)(43)(21)(55)(97)(88)(96)(103)(94)
Interest expense000000000(2)
Interest & investment income0001003788
Other income (expense), net00(2)1003786
Pre-tax income(11)(52)(45)(21)(54)(97)(85)(88)(95)(89)
Income tax expense0(6)(6)0(5)—0——(1)
Net income194(46)(39)(21)(49)(97)(85)(88)(95)(88)
EPS — basic$2.97———($1.91)($2.35)($1.81)($1.66)($1.34)($1.00)
EPS — diluted$2.95———($1.91)($2.35)($1.81)($1.66)($1.34)($1.00)
Shares outstanding — basic (M)65———264147537188
Shares outstanding — diluted (M)66———264147537188

Showing the latest 10 of 16 fiscal years.

  • ⚑ Weighted-average shares changed ÷2.50 between FY2016 and FY2020 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.
  • ⚑ Weighted-average shares changed ×1.58 between FY2020 and FY2021 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.